Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

June 5, 2024

Study Completion Date

June 19, 2024

Conditions
CoughIdiopathic Pulmonary Fibrosis
Interventions
DRUG

Orvepitant Maleate

Orvepitant tablets 30mg or 10mg

DRUG

Placebo

Placebo tablets to match orvepitant 30mg and 10mg tablets

Trial Locations (37)

19140

Temple University, Philadelphia

20904

Jadestone Clinical Research, LLC, Silver Spring

22908

University of Virginia Health System, Charlottesville

27403

PulmonIx, LLC, Greensboro

28277

American Health Research, Charlotte

29424

Medical University of South Carolina, Charleston

37204

Vanderbilt University Medical Center, Nashville

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic, Rochester

60153

Loyola University Chicago, Maywood

75246

Baylor University, Dallas

77598

Clear Lake Health, Webster

80206

National Jewish Health, Denver

84108

University of Utah, Salt Lake City

90033

University of Southern California, Los Angeles

94143

University of California, San Francisco

6419 PC

Zuyderland Medical Centre, Heerlen

3435 CM

Sint Antonius Hospital, Nieuwegein

3015 GD

Erasmus University Medical Centre, Rotterdam

8025 AB

Isala Ziekenhuis, Zwolle

RG1 5AN

Royal Berkshire Hospital, Reading

HU16 5JQ

Castle Hill Hospital, Cottingham

L34 1BH

MAC Clinical Research, Prescot

BT41 2RL

Antrim Area Hospital, Antrim

BT47 6SB

Altnagelvin Area Hospital, Londonderry

OX3 7LE

Churchill Hospital, Headington

PH1 1NX

Perth Royal Infirmary, Perth

EH16 4SA

Royal Infirmary of Edinburgh, Edinburgh

S75 3DL

MAC Clinical Research, Barnsley

LS10 1DU

MAC Clinical Research, Leeds

B9 5SS

Heartlands Hospital, Birmingham

CB2 0AY

Royal Papworth Hospital, Cambridge

EX2 5DW

Royal Devon and Exeter Hospital, Exeter

SE1 9RT

Guy's Hospital, London

M13 9NQ

MAC Clinical Research, Manchester

NG5 1PB

Nottingham City Hospital, Nottingham

SO16 6YD

Southampton General Hospital, Southampton

Sponsors
All Listed Sponsors
collaborator

Pharm-Olam International

INDUSTRY

lead

Nerre Therapeutics Ltd.

INDUSTRY

NCT05185089 - Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter